Dry powder inhaler and system for drug delivery

Patent metadata

Field	Value
Publication number	US-11998683-B2
Application number	US-202217665902-A
Country	US
Kind code	B2
Filing date	Feb 7, 2022
Priority date	Jun 13, 2008
Publication date	Jun 4, 2024
Grant date	Jun 4, 2024

Abstract

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

First claim

We claim:

1. An inhaler comprising: a housing; a mouthpiece having an oral placement section and an extended portion, the extended portion extending from the oral placement section, configured as a cover which extends over and engages the housing by a locking mechanism; a gear mechanism; and a sled including a cartridge holder; wherein actuation of the gear mechanism moves the sled in a concurrent movement within the housing and wherein the movement of the sled is configured to translocate a cartridge comprising a container, both in the cartridge holder, from a powder containment position to a dosing position.

2. The inhaler of claim 1 , wherein the housing is configured to accommodate the cartridge container.

3. The inhaler of claim 1 , wherein the container is configured to house a dry powder medicament including at least one active ingredient.

4. The inhaler of claim 3 , wherein the at least one active ingredient is a peptide, polypeptide, protein, or a combination thereof.

5. The inhaler of claim 3 , wherein the at least one active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, an argatroban, anti-SSX-241-49, anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

6. The inhaler of claim 3 , wherein the dry powder medicament comprises a diketopiperazine.

7. The inhaler of claim 6 , wherein the diketopiperazine is

8. The inhaler of claim 3 , wherein the at least one active ingredient is a small organic molecule.

9. The inhaler of claim 3 , wherein the at least one active ingredient is an antibiotic.

10. The inhaler of claim 1 , wherein the locking mechanism is a protrusion.

11. An inhaler comprising:
a housing;
a mouthpiece having an oral placement section and an extended portion, the extended portion extending from the oral placement section, configured as a cover which extends over and engages the housing by a locking mechanism;
a gear mechanism; and
a sled including a cartridge holder;
wherein actuation of the gear mechanism moves the sled to translocate a cartridge in the cartridge holder from a containment position to a dosing position, and wherein in the dosing position 10% to 70% of total airflow through the inhaler enters and exits the cartridge.

12. The inhaler of claim 11 , wherein the cartridge includes a medicament container.

13. The inhaler of claim 12 , wherein the medicament container is configured to house a dry powder medicament.

14. The inhaler of claim 13 , wherein the dry powder medicament includes at least one active ingredient.

15. The inhaler of claim 14 , wherein the at least one active ingredient is a peptide, polypeptide, protein, or a combination thereof.

16. The inhaler of claim 14 , wherein the at least one active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, an argatroban, anti-SSX-241-49, anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

17. The inhaler of claim 14 , wherein the dry powder medicament comprises a diketopiperazine.

18. The inhaler of claim 17 , wherein the diketopiperazine is

19. The inhaler of claim 11 , wherein the locking mechanism is a protrusion.

Assignees

• Mannkind Corp

Inventors

• Smutney Chad C
• Kinsey P Spencer
• Sahi Carl R
• Adamo Benoit
• Polidoro John M
• Mclean Scott
• Overfield Dennis
• Bryant Anthony

Classifications

• A61M15/0045 Primary

  using multiple prepacked dosages on a same carrier, e.g. blisters · CPC title

• A61K9/0075

  for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title

• A61K38/1709

  from mammals · CPC title

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61K38/26

  Glucagons · CPC title